BB-1701 is under clinical development by Bliss Biopharmaceutical (Hangzhou) and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase I drugs for Gastroesophageal (GE) Junction Carcinomas have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BB-1701’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BB-1701 is under development for the treatment of HER2 positive solid tumors including breast cancer, colon cancer, bladder cancer, gastric cancer, urothelial carcinoma and gastroesophageal junction cancer. It is administered by intravenous route.
Bliss Biopharmaceutical (Hangzhou) overview
Bliss Biopharmaceutical (Hangzhou), is a biopharmaceutical company that discovery, development and commercialization of biotherapeutics for rare diseases. The company is headquartered China.
For a complete picture of BB-1701’s drug-specific PTSR and LoA scores, buy the report here.